Estrogen-gestagen realizing systems: new view on contaception (review of the literature)
- 作者: Nazarova NM1, Prilepskaya VN1, Nazarova NM1, Prilepskaya VN1
-
隶属关系:
- 期: 编号 14 (2009)
- 页面: 10-15
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278006
- ID: 278006
如何引用文章
全文:
详细
Advances in hormonal contraception have led to the creation of new estrogen-progestin-releasing systems as NovaRing vaginal ring and transdermal patch EVRA. We consider their contraceptive efficacy, effect on the menstrual cycle, body weight, and metabolic parameters. It is emphasized that these systems have a number of advantages (the release of small doses of hormones, the absence of daily fluctuations in the hormone excretion and the primary effect of passing through the liver, usability, minimal systemic effects, etc.), making them the most prospective methods of contraception.
参考
- Гормональная контрацепция / Под ред. В.Н. Прилепской. М., 1998. 216 с.
- Бороян Р.Г. Клиническая фармакология для акушеров-гинекологов. М., 1999. С. 8-123.
- Караченцев А.Н. Гепатобилиарная система как мишень нежелательных эффектов лекарственных эстрогенов и гестагенов // Российский вестник акушера-гинеколога. 2004. № 6. С. 20-25.
- Прилепская В.Н., Острейкова Л.И. Клинические аспекты применения внутриматочной левоноргестрел-рилизинг системы у женщин в пременопаузе. Тезисы Российского конгресса по гинекологической эндокринологии и менопаузе. М., 2004. С. 47-48.
- Прилепская В.Н. Новаринг - контрацепция, анатомия, сексология // Гинекология. 2004. Т. 6. № 6.
- Прилепская В.Н., Назарова Н.М. Новые технологии в контрацепции: гормональные рилизинг-системы // Гинекология. 2005. Т. 7. № 1.
- Прилепская В.Н., Назарова Н.М. Трансдермальная контрацептивная система ЕВРА // Фарматека. 2005. № 15. С. 8-10.
- Серов В.Н., Пауков С.В. Оральная гормональная контрацепция. М., 1998. 167 с.
- Стрижаков А.Н., Давыдов А.И., Шахламова М.Н. Современные методы контрацепции. М., 1997. 30 с.
- Abrams L, Skee D, Natarajan J, et al. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinylestradiol at four application sites. Br J Clin Pharmacol 2002;53:141-46.
- Ahren T, Victor A, Lithell H, et al. Ovarion function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins. Contraception 1983;28:315-27.
- Archer D, Bigrigg A, Smallwood G, et al. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American Women. Fertil Steril 2002;77(2):27-31.
- Аrcher DF, Darney P. Local tolerability jf a combined contraceptive ring. Manuscript in preparation; 2003.
- Audet MC, Moreau M, Koltun WD, et al. Evaluation of contracrptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive^ a randomized controlled trial. JAMA 2001;285:2347-54.
- Barbosa I, Bacos O, Olsson SE, et al. Ovarian function duaring use of levonolgestrel-releasing IUD. Contraception 1990;42:51.
- Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with NuvaRing, the combined contraceptive vaginal ring and oral levonorgestrel/ethinylestradiol. Am J Obstet Gynecol 2002;186(3):389-95.
- Dieben TO, Roumen FJ, Apter D, et al. Efficacy, cycle control and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100(3):585-93.
- Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacocinet 2005;44(4):429-38.
- Goldfien A. The gonadal hormones & inhibitors. In: Basic & clinical pharmacology. 7th ed. Katzung BG (ed). Stamford, CT: Appleton & Lange, 1998.
- Jackson R, Newton JR. The in vivo release characteristics of a multi-compartment vaginal ring releasing 3 keto-desogestrel. Contraception 1989;40:615-21.
- Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 1988;38:325-32.
- Magnusdottir SD, Bjarnadottir RI, Sigurdardottir K, et al. The combined contrceptive vaginal ring (NuvaRing) and hemostasis: a comparative study. Manuscript in preparation, 2002.
- Mishell DR, Moore DE, Roy S, et al. Clinical perfomance and endocrine profiles with contraceptive vaginal ring containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol 1978;130:55-62.
- Mulders TMT, Dieben T. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001;75:865-70.
- Mulders TMT, Dieben T, Coelingh Bennink HJT. Ovarian function with a novel combined contraceptive vaginal ring. Manuscript in preparation, 2002.
- National Institute of Child Health and Human Development. Contraception and Reproductive Health Branch. Report to the NACHHD Council September 1999. Weight, obesity, and oral contraceptive failure. 2001. Available at: http://156.40.88.3/publication@/pubs/coun_crh.htm.Accessed September 19, 2001.
- Newton JR., Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995;1:231-63.
- Novak A, de la Lodge C, Abetz L. Valuation of NuvaRing acceptability in 14 countries. Presented at the 17th World Congress of Feritity and Sterility, Melbourne, 2001.
- Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999;180:276-79.
- Roumen FJME, Boon ME, van Velzen D, et al. The cervico-vaginal epithelium during 20 cycles use of a combined contraceptive vaginal ring. Hum. Reprod 1996;11:2443-48.
- Roumen FJME, Apter D, Mulders TMT, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinylestradiol. Hum Reprod 2001;16:469-75.
- Sibai BM, Odlind V, Meador ML, et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Orto bvraEvra). Fertil Steril 2002;77(Suppl. 2):19-26.
- Smallwood G, Meador M, Lenihan J, et al. For the ORTHO EVRA/EVRA 002 Study Group. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.
- Timmer CJ, Apter D, Voortman G. Pharmacokinetics of 3 keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. Contraception 1990;42:629-42.
- Timmer CJ, Mulders TMT. Fharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Рharmacokinet 2000;39:233-42.
- Tuppurainen M, Klimscheffskij R, Venhola M, et al. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study. Manuscript in preparation; 2003.
- Verhoeven CHJ, van den Heuvel MW, Mulders TMT, et al. The contraceptive vaginal ring, NuvaRing and, antimycotic co-medication. Manuscript submitted; 2003.
- Zacur HA, Hedon B, Mansour D, et al. Integrated summary of Ortho Evra/Evra cjntraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002;77(Suppl. 2):S32-35.
- Zibners A, Cromer BA, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol 1999;12:90-94.
- Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002;77(2):13-18.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2381&mid=1085056570&magid=178
补充文件
![](/img/style/loading.gif)